Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Esophageal cancer is one of the most common malignancies in China, and esophageal squamous cell carcinoma (ESCC) is the predominant histological type. Surgical resection is still a standard therapeutic approach for patients with resectable ESCC, but the prognosis is still disappointing. Although neoadjuvant chemoradiotherapy plus surgery is currently recommended for patients with locally advanced ESCC, it is still an infrequently used procedure in China. The efficacy of adjuvant therapy on ESCC is still controversial. Recently, the CheckMate 577 trial showed that adjuvant nivolumab therapy cou

Trial Details

NCT ID
NCT05984342
Phase
PHASE1
Sponsor
Affiliated Cancer Hospital of Shantou University Medical College
Status
RECRUITING
Cancer Type
Squamous Cell Esophageal Cancer
Interventions
  • Tislelizumab
Locations (sample)
  • Shantou, Guangdong, China|23.35489,116.67876

Key Eligibility Criteria

  • Aged between 18 and 70 years
  • Untreated before surgery (e.g. radiotherapy, chemotherapy, target therapy and immunotherapy)
  • Histologically documented squamous cell carcinoma of the thoracic esophagus with positive lymph nodes (T1-3N1-3M0)
  • undergoing radical esophagectomy

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Squamous Cell Esophageal Cancer Trials on Trialify →